Trial · NCT03896503
Participant flow80
How many started, completed or left each group, period by period.
1 to 20 of 80
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Initial Subgroup and Arm Enrollment | STARTED | Platinum Response - Sensitive: Topotecan Monotherapy | 10 | |
| Initial Subgroup and Arm Enrollment | STARTED | Platinum Response - Sensitive: Topotecan & M6620 (VX-970) Combination Therapy | 20 | |
| Initial Subgroup and Arm Enrollment | STARTED | Platinum Response - Sensitive: Enrolled But Not Treated | 10 | |
| Initial Subgroup and Arm Enrollment | STARTED | Platinum Response - Resistant: Topotecan Monotherapy | 11 | |
| Initial Subgroup and Arm Enrollment | STARTED | Platinum Response - Resistant: Topotecan & M6620 (VX-970) Combination Therapy | 23 | |
| Initial Subgroup and Arm Enrollment | STARTED | Platinum Response - Resistant: Enrolled But Not Treated | 9 | |
| Initial Subgroup and Arm Enrollment | STARTED | Exploratory Cohort: Topotecan & M6620 (VX-970) Combination Therapy | 18 | |
| Initial Subgroup and Arm Enrollment | STARTED | Exploratory Cohort: Enrolled But Not Treated | 3 | |
| Initial Subgroup and Arm Enrollment | Not Treated | Platinum Response - Sensitive: Topotecan Monotherapy | 1 | |
| Initial Subgroup and Arm Enrollment | Not Treated | Platinum Response - Sensitive: Topotecan & M6620 (VX-970) Combination Therapy | 0 | |
| Initial Subgroup and Arm Enrollment | Not Treated | Platinum Response - Sensitive: Enrolled But Not Treated | 10 | |
| Initial Subgroup and Arm Enrollment | Not Treated | Platinum Response - Resistant: Topotecan Monotherapy | 1 | |
| Initial Subgroup and Arm Enrollment | Not Treated | Platinum Response - Resistant: Topotecan & M6620 (VX-970) Combination Therapy | 2 | |
| Initial Subgroup and Arm Enrollment | Not Treated | Platinum Response - Resistant: Enrolled But Not Treated | 9 | |
| Initial Subgroup and Arm Enrollment | Not Treated | Exploratory Cohort: Topotecan & M6620 (VX-970) Combination Therapy | 2 | |
| Initial Subgroup and Arm Enrollment | Not Treated | Exploratory Cohort: Enrolled But Not Treated | 3 | |
| Initial Subgroup and Arm Enrollment | Off Treatment | Platinum Response - Sensitive: Topotecan Monotherapy | 7 | |
| Initial Subgroup and Arm Enrollment | Off Treatment | Platinum Response - Sensitive: Topotecan & M6620 (VX-970) Combination Therapy | 17 | |
| Initial Subgroup and Arm Enrollment | Off Treatment | Platinum Response - Sensitive: Enrolled But Not Treated | 0 | |
| Initial Subgroup and Arm Enrollment | Off Treatment | Platinum Response - Resistant: Topotecan Monotherapy | 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03896503/flow